Ocular Therapeutix (OCUL) reported a Q3 net loss Thursday of $0.22 per diluted share, narrowing from a loss of $0.25 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.24.
Revenue for the quarter ended Sept. 30 was $15.4 million, up from $15.1 million a year earlier.
Analysts surveyed by Capital IQ expected $17.1 million.
Cash and cash equivalents totaled $427.2 million as of Sept. 30, up from $195.8 million on Dec. 31, which the company said it believes is sufficient to fund operations into 2028.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments